
NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the common shares.
The Company has a right to a review of the staff's determination to delist the common shares by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the Company's common shares upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.
Contacts
Company Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555, press #5 for Corporate and then #2 for Investor Relations
NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304209507/en/
© 2025 Business Wire